title: Disparate effects of pramipexole on locomotor activity and sensorimotor gating in Sprague-Dawley rats.
abstract: Prepulse inhibition (PPI) of acoustic startle and locomotor activity are both widely studied in the preclinical development of dopaminergic agents, including those acting at D3 dopamine receptors. In mice, the dopamine D3 receptor-preferential agonist pramipexole (PPX) alters locomotor activity in a biphasic manner at doses that have no effect on PPI. The present study examined the time-course of PPX effects on locomotion and PPI in rats. In adult male Sprague-Dawley rats, PPX (0, 0.1, 0.3, 1.0mg/kg) was injected prior to measurement of locomotor activity for 90 min in photobeam chambers. Based on disparate early vs. late effects of PPX on locomotion, the effects of PPX (0 vs. 0.3mg/kg) on PPI were tested 20 and 80 min after injection. All doses of PPX decreased locomotor activity for 30 min compared to vehicle, and the higher doses stimulated hyperlocomotion later in the session; the late hyperlocomotion, but not the early hypolocomotion, was blocked by the D2-selective antagonist, L741626 (1.0mg/kg sc). In contrast to its locomotor effects, PPX caused a similar reduction in PPI at 20 and 80 min after administration. These findings suggest both a temporal and pharmacological dissociation between PPX effects on locomotor activity and PPI; these two behavioral measures contribute non-redundant information to the investigation of D3-related behavioral pharmacology.
authors.affiliation: Department of Psychiatry, University of California San Diego School of Medicine, La Jolla, CA 92093-0804, USA.
authors.forename: Wei-li
authors.initials: WL
authors.lastname: Chang
authors.forename: Michelle R
authors.initials: MR
authors.lastname: Breier
authors.forename: Alex
authors.initials: A
authors.lastname: Yang
authors.forename: Neal R
authors.initials: NR
authors.lastname: Swerdlow
mesh_terms: D000818:Animals; D052160:Benzothiazoles / Q000494:pharmacology*; D003627:Data Interpretation, Statistical; D018491:Dopamine Agonists / Q000494:pharmacology*; D018492:Dopamine Antagonists / Q000494:pharmacology; D065127:Dopamine D2 Receptor Antagonists; D004305:Dose-Response Relationship, Drug; D007211:Indoles / Q000494:pharmacology; D008297:Male; D009043:Motor Activity / Q000187:drug effects*; D010880:Piperidines / Q000494:pharmacology; D000077487:Pramipexole; D051381:Rats; D017207:Rats, Sprague-Dawley; D050637:Receptors, Dopamine D3 / Q000187:drug effects*; D013216:Reflex, Startle / Q000187:drug effects; D055139:Sensory Gating / Q000187:drug effects*
chemical_list: D052160:Benzothiazoles; D018491:Dopamine Agonists; D018492:Dopamine Antagonists; D065127:Dopamine D2 Receptor Antagonists; D007211:Indoles; D010880:Piperidines; D050637:Receptors, Dopamine D3; C104750:3-(4-(4-chlorophenyl-4-hydroxypiperidino)methyl)indole; D000077487:Pramipexole